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CASE SERIESGemcitabine-induced pseudocellulitis in a patient
with nonesmall cell lung carcinoma
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arm after gemcitabine chemotherapy.INTRODUCTION
Gemcitabine (2,2-difluorodeoxycytidine) is a
nucleoside analogue used as a chemotherapeutic
agent to treat various malignancies. The common
side effects of gemcitabine include myelosuppres-
sion, gastrointestinal disturbances, influenzalike
symptoms, and elevation of liver enzyme levels.
Gemcitabine is also associated with cutaneous
adverse effects such as rash, alopecia, pruritus,
radiation recall dermatitis, hypersensitivity reactions,
hyperpigmentation, and erysipeloid reactions.1-3
There are also a few isolated cases of livedo
reticularis, sclerodermalike changes, Sweet’s
syndrome, and toxic epidermal necrolysis.3
Rarely, gemcitabine is associated with pseudo-
cellulitis, a nonnecrotizing inflammation of the
dermis and subcutis from a noninfectious etiology,
which could be confused clinically for cellulitis.1,4
We report a case of recurrent gemcitabine-induced
pseudocellulitis after the use of gemcitabine and
carboplatin combination therapy.CASE PRESENTATION
A 77-year-old man was receiving gemcitabine and
carboplatin for stage IV nonesmall cell carcinoma of
the lung and metastases to the brain. He previously
received gamma knife and radiotherapy to his chest
and carboplatin/pemetrexed chemotherapy.
The patient originally presented as an outpatient
with an acute onset of bilateral lower extremity
erythema 2 days after receiving his third cycle
of gemcitabine chemotherapy. Cephalexin was
initiated for a presumptive diagnosis of bacterial
cellulitis, and when he did not improve after 3 days,the Department of Dermatology,a and Departments of
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varik@uphs.upenn.edu.he switched to clindamycin. After still not improving,
he presented to the emergency department.
Intravenous vancomycin was initiated; however,
chills and rigors developed abruptly, and
vancomycin was discontinued. The dermatology
team was then consulted.
On assessment, he denied recent trauma to his
legs. He reported 2 similar previous episodes of
erythema of the extremities a few days after the
gemcitabine treatment, which had both resolved
spontaneously within 1 week after the onset. The
first episode involved his right forearm (Fig 1), and
the second episode was described as red patches on
his lower extremities. Each subsequent episode
seemed to be more exuberant and last longer than
the prior episode.
On examination, the patient was found to be
afebrile. There was well-demarcated, confluent
erythema of bilateral lower extremities (left greater
than right), extending from the dorsal surface of his
feet to the upper shin (Fig 2). He also had 21 pitting
pedal edema extending up to his upper shins. ThereJAAD Case Reports 2015;1:178-81.
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Fig 2. Current case of pseudocellulitis on both lower
extremities.
Fig 3. Histology was consistent with hypersensitivity
reaction, with edema and sparse mixed inflammation.
(Hematoxylin-eosin staining; original magnification:
3200.)
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were felt bilaterally. The rest of his physical
examination findings were essentially normal.
Diagnostic tests were done, and pending results,
the primary medical team started treatment with
nafcillin to cover for possible cellulitis. The
laboratory panel results showed a normal white
blood cells count of 4.43 109 cells/L, and the patient
remained afebrile. A biopsy specimen taken for
histology was consistent with hypersensitivity
reaction, with edema and sparse mixed inflamma-
tion with lymphocytes, occasional neutrophils, and
rare eosinophils (Fig 3). Tissue culture showed no
growth.
Based on the absence of fever, normal white cell
count, tissue cultures and biopsy result, recurrent
nature of the disease, and temporal relation
between of the appearance of the lesions and the
administration of gemcitabine, a diagnosis of
gemcitabine-induced pseudocellulitis was made,
and antibiotics were discontinued. The patient was
treated with 0.1% triamcinolone acetonide cream
under occlusion and compression stockings to
manage lymphedema. The erythema regressed
over the next 3 days, and he was discharged from
the hospital in a stable condition. Recommendations
were made not to withdraw gemcitabine chemo-
therapy, as the patient was responding remarkably tothis treatment. We recommended similar treatment, if
any erythema was detected during future gemcita-
bine cycles. After discharge, the patient was seen in
the outpatient clinic with no further complaints.
DISCUSSION
Gemcitabine is a pyrimidine antimetabolite,
which is incorporated as an active nucleotide
metabolite into DNA, resulting in chain termination
and inhibition of DNA synthesis. Gemcitabine is used
as treatment for a variety of malignancies. The
American Society of Clinical Oncology guidelines
recommend combination of platinum-based
doublets with drugs such as gemcitabine as the
preferred chemotherapy for advanced nonesmall
cell carcinoma of the lung.5 As the therapeutic use of
gemcitabine expands, awareness of its potential
toxicities is increasingly important.
Gemcitabine has been associated with several
cutaneous toxicities, notably, radiation recall
reactions.6 Because gemcitabine is a radiosensitizer,
radiation recall may occur when the agent is given
Table I. Review of previous published cases of gemcitabine-induced pseudocellulitis in absence of previous radiation exposure
Study Tumor type
Location of
pseudocellulitis
Associated lymphedema
with pseudocellulitis
Time from last
dose of gemcitabine
to reaction
Treatment of gemcitabine-induced
pseudocellulitis
Brandes et al 200010 Metastatic NSCLC and
breast cancer,
metastatic endometrial
cancer, metastatic
endometrial cancer
Bilateral legs,
abdomen and
thighs, thigh
Pre-existing lymphedema
of both lower extremities,
lymphatic edema of lower
abdomen and thighs, thigh
edema postosteosynthesis
All 3 presented
within 2 days
Resolved within 14 days without
specific treatment
Curtis et al 20142 Metastatic perivascular
sarcoma of the pelvis
Bilateral lower legs Lower extremity edema caused
by lymphatic obstruction
Within 5 days Spontaneous resolution and
discontinuation of gemcitabine
therapy
Dasanu and Bockorny
20141
Adenocarcinoma of the
pancreas
Bilateral lower legs Moderate bilateral pedal edema Within a few
weeks of therapy
Reassurance, spontaneous resolution
Korniyenko et al
20124
Squamous cell lung
carcinoma
Bilateral lower legs Bilateral lower extremity edema Less than 1 day Diphenhydramine with NSAIDs for
symptomatic management.
Kuku et al 200211 Mesothelioma Left elbow and knee None 2 days Spontaneous resolution
Obeid and Venugopal
20139
Metastatic liver disease Bilateral lower legs Bilateral lower extremity edema 2 days Self-resolution after initial antibiotic
therapy
Singh and Hampole
20123
Metastatic pancreatic
adenocarcinoma
Bilateral lower legs Bilateral lower extremity edema 7 days Withdrawal of gemcitabine and
symptomatic management with
NSAIDs
Zustovich et al 200612 Metastatic renal cancer Bilateral lower legs
(R[ L)
Mild bilateral lower extremity
edema
6 days
NSAIDs, Nonsteroidal anti-inflammatory drugs; NSCLC, Nonesmall cell lung carcinoma.
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radiation treatment. The pathophysiology of
radiation recall is hypothesized to be caused by
vascular damage and increased localized
permeability of the skin capillaries in areas
previously treated with radiotherapy. Another
hypothesis proposes a drug hypersensitivity
mechanism.7
However, recently, a new phenomenon known as
gemcitabine-related pseudocellulitis, occurring in
the absence of prior radiotherapy, has been
described (Table I). Gemcitabine-related pseudocel-
lulitis may occur in an area of lymphedema, as one of
the episodes of this case. The etiology of the
lymphedema in this case is unknown and may be a
side effect of gemcitabine, as seen in some other case
reports. The pathophysiology of this reaction is still
unknown, although it is theorized that areas of
impaired lymphatic drainage lead to drug
permeation into interstitial fluid, drug accumulating
in the subcutaneous tissue, and inadequate drug
inactivation in subcutaneous tissue.2,4
The evaluation of gemcitabine-induced
pseudocellulitis poses a challenge because many
possible etiologies exist for cutaneous eruptions in
cancer patients. Clinical judgment, laboratory
analysis, tissue cultures, and histopathology can
help distinguish pseudocellulitis from infective
cellulitis. Wells syndrome (eosinophilic cellulitis)
could also be considered clinically; however, it is
distinguished histologically because of the marked
infiltrate of eosinophils in the dermis. Also, because
gemcitabine is often used in combination with other
chemotherapeutic agents, it is important to ensure a
reaction observed is not caused by the other agent.
In this case report, the other agent used was
carboplatin, a DNA alkylating agent, which generally
has minimal skin toxicity.8
The duration of gemcitabine-induced pseudo-
cellulitis is proposed to be related to the drug’s
pharmacokinetics and may exist until the drug is
displaced from the subcutaneous tissue of the
affected area.2 Nonsteroidal anti-inflammatorydrugs, diphenhydramine, and topical steroids may
be given for symptomatic therapy.1,4,9
This case reiterates the need for awareness of this
adverse reaction by the medical team. Awareness is
vital to help avoid misdiagnosis as infectious
cellulitis, unnecessary hospitalization, and exposure
to antibiotics and enable gemcitabine chemotherapy
to be continued with proper precautions.REFERENCES
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